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Directed by: Dr. Rajalingam Dakshinamurthy, Dr. Cathleen Webb and Dr. Stuart Burris 
Department of Chemistry     Western Kentucky University 
 The antimicrobial properties of dextrose encapsulated gold nanoparticles (dGNPs) 
with average diameters of 25 nm, 60 nm, and 120 nm (± 5 nm) synthesized by green 
chemistry principles were investigated against both Gram-negative and Gram-positive 
bacteria. Studies were performed involving the effect of the dGNPs on the growth, 
morphology and the ultrastructural properties of bacteria. dGNPs were found to have 
significant dose dependent antibacterial activity which was directly proportional to their 
size and also their concentration. The microbial assays revealed the dGNPs to be 
bacteriostatic as well as bactericidal. The dGNPs exhibited their bactericidal action 
through the disruption of the bacterial cell membrane causing leakage of cytoplasmic 
content. The overall outcomes of this study suggest that dGNPs hold promise as a potent 
antimicrobial agent against a wide range of disease causing bacteria and can control and 
prevent possible infections or diseases.                                                                                              
                                                                                                                            
   
 INTRODUCTION 
Definitons of nanotechnology are as diverse as the applications that are available. 
It can be defined as the ability to design and control the structure of an object at all length 
scales from the atom up to macro scale. The particles ranging from 10-100 nm are known 
as nanoparticles (Figure 1).1 One of the reasons for the unique qualities of nanoparticles 
is the very small size of the materials.  
 
 
Figure 1: Scale for the comparison of Nanoparticles size. 
At the nanoscale, many common materials exhibit unusual properties, such as 
lower resistance to electricity, lower melting points or faster chemical reactions. One 
such metal is gold (Au) which at the macroscale is shiny and yellow. Gold nanoparticles 
appear red in color when they are made to a size of 25 nm.2 These smaller particles 
interact differently with light, so at each size range they appear in a different color. 
Depending on the size and shape of the particles, gold can appear red, yellow, or blue3. 
Gold nanoparticles may lead to new solutions to many of the problems the world is 
facing. 
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Nanoparticles are more reactive because they have more surface area than macroscale 
particles. 
Today nanoparticle research is currently an area of intense scientific interest due 
to a wide variety of potential applications in biomedical, optical and electronic fields 
(Figure 2). GNPs are currently being used as a drug to cure various diseases, including 
certain life threatening diseases like cancer, Alzheimer’s disease, etc. Some of the 
applications of nanoparticles in the field of biology/ medicine include:4-7 
 Fluorescent biological labels 
 Drug and gene delivery  
 Bio-detection of pathogens 
 Detection of proteins 
 Tissue engineering 
 MRI contrast enhancement 
 Tumor destruction  
 Antimicrobial agents 
 3 
 
 
 
Figure 2: Schematic representation showing various applications of nanotechnology. 
Among all the applications, most of the applications affect the environment and human 
body. Hence, there is a need for environmentally friendly approach towards 
nanotechnology. 
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Multidrug-resistant (MDR) bacteria represent a major threat to the success of 
many branches of medical sciences. Some patients are especially vulnerable of acquiring 
MDR bacterial infections as a consequence of treatments for illnesses such as organ 
transplant, hemodialysis and various types of cancer.8 Each year at least 150,000 people 
die around the world due to the infection of a particular MDR bacterium.9 Therefore, 
there is an immense need for new strategies to design antibacterial agents.10 Depending 
upon the nature of the cell wall, bacteria are divided into two types: 
 Gram Positive  
 Gram Negative 
The basic differences between the gram-negative and gram-positive bacteria are 
that: Gram-negative have a cell wall that does not retain crystal violet dye, whereas, the 
gram-positive organisms have a cell wall that retains the stain. The structure, 
components, and functions of the cell wall distinguish Gram positive from Gram negative 
bacteria (Figure 3). 
Gram Positive Bacteria:  
       A Gram positive bacterium has a thick, multilayered cell wall consisting mainly 
of peptidoglycan (150 to 500 °A), surrounding the cytoplasmic membrane. The 
peptidoglycan is a meshlike exoskeleton similar in function to the exoskeleton of an 
insect. The peptidoglycan is essential for the structure, for replication, and for survival in 
the normally hostile conditions in which bacteria grow. During infection, the 
peptidoglycan can interfere with phagocytosis, is mitogenic (stimulates mitosis of 
lymphocytes), and has pyrogenic activity (induces fever). The Gram positive cell wall 
may also include other components such as teichoic and lipoteichoic acids and complex 
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polysaccharides (usually called C polysaccharides). Proteins such as the M protein of 
streptococci and R protein of staphylococci also associate with the peptidoglycan.11 
Gram Negative Bacteria: 
       Gram negative cell walls are more complex than Gram positive cell walls, both 
structurally and chemically. Structurally, a Gram negative cell wall contains two layers 
external to the cytoplasmic membrane. Immediately external to the cytoplasmic 
membrane is a thin peptidoglycan layer, which accounts for only 5% to 10% of the Gram 
negative cell wall by weight. There are no teichoic or lipoteichoic acids in the Gram 
negative cell wall. External to the peptidoglycan layer is the outer membrane, which is 
unique to Gram negative bacteria. The area between the external surface of the 
cytoplasmic membrane and the internal surface of the outer membrane is referred to as 
the periplasmic space. In the case of pathogenic Gram negative species, many of the lytic 
virulence factors such as collagenases, hyaluronidases, proteases, and beta-lactamase are 
in the periplasmic space.12 
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Figure 3: Comparison of the Gram positive and Gram negative bacterial cell walls. (A) 
Gram positive bacterium has a thick peptidoglycan layer that contains teichoic and 
lipoteichoic acids. (B) Gram negative bacterium has a thin peptidoglycan layer and an 
outer membrane that contains lipopolysaccharide, phospholipids, and proteins.12  
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Nanoparticles (NPs) have been used to synthesize or to improve the remedial 
efficacy of antibacterial agents.13-19 This application may benefit from one or a few 
combinations of the properties of NPs:  
 Act as a carrier of drugs to effectively pass through cell membranes. 
 Able to concentrate drugs on their surfaces, resulting in polyvalent effects. 
 Specifically attack biological targets after modification with target molecules. 
NPs for this purpose are generally synthesized by using various metals and polymers.20,21 
Unfortunately, the undesirable properties such as cellular toxicity and instability of these 
NPs limit their application.22,23 On the other hand, gold nanoparticles (GNPs) have 
attracted a significant interest because of convenient surface bioconjugation, remarkable 
plasmon-resonant optical properties, chemical stability and non-toxicity.24-27 Studies have 
also shown that the GNPs are useful to improve the efficacy, drug delivery, target 
specificity and biodistribution of the drugs which enhances the antibacterial activity 
against MDR.20-27 For the synthesis of GNPs, various wet chemical methods employing 
various polar and nonpolar solvents have been used.28, 29 Among them, the most common 
methods includes the reduction of tetrachloroauric acid (HAuCl4) by excess sodium 
borohydride (NaBH4) or sodium citrate in the presence of stabilizing/ capping ligands 
such as citrate, thiolates, amines, phosphanes, carbonyls, dendrimers, hydroquinones and 
surfactants. For example, the use of hydroquinone, a suspected carcinogen, with 
traditional citrates methods leaves the product GNPs with trace amounts of organic 
solvents.  This raises environmental concerns and also limits the biocompatibility and 
biomedical application of GNPs, because of its cellular toxicity. 
 8 
 
 However, the use of complicated non-bio/ non-ecofriendly chemical synthesis 
processes and dependence on external sources (such as laser pulses) for the synthesis 
and/or the activation of GNPs, limits their environmental/bio-compatibility.30-34 Studies 
have demonstrated that the size of the GNPs strongly influence their physical, chemical 
and biological properties.35,36 Therefore, there is a need for environmentally friendly 
synthesis of GNPs with different sizes for various biomedical applications including 
those with antibacterial activity.37  
This report is focused on the antibacterial activity of dGNPs which were 
synthesized by employing a ‘completely green’ method as shown in our previously 
published article.38 dGNPs of three different sizes were synthesized having average 
diameter of 25 nm, 60 nm, and 120 nm (±5). Resulting dGNPs were nearly spherical, 
monodispersed, stable, and water soluble. The dGNPs were prepared using dextrose as 
both reducing and capping agent.  
We have explored the antibacterial activity of the sugar encapsulated 
biocompatible GNPs against both Gram-negative (Escherichia coli) and Gram-positive 
(Staphylococcus epidermidis) bacteria. Investigation of the bacterial growth kinetics and 
growth inhibition in the presence of the dGNPs at various concentrations was performed 
using a real-time spectrophotometric assay. Antibacterial activity and efficacy were 
further validated by turbidimetry and spread plate assays. To understand the mechanism 
of action, we performed fluorescence microscopy and observed ultrathin slices of dGNP 
treated bacterial cells under the transmission electron microscope (TEM). 
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MATERIALS AND METHODS 
Reagents and Material: 
 KAuCl4/ HAuCl4, Luria-Bertani (LB) broth, LB agar, Soy tryptic agar, 
propidium iodide and dextrose were purchased from Aldrich, St. Louis, MO. E. coli and 
S. epidermidies were purchased from Invitrogen, Carlsbad, CA or obtained from Western 
Kentucky University culture collection. Analytical grade chemicals were typically used.  
Synthesis and Characterization of dGNPs: 
 Gold nanoparticles were synthesized according to our previously published, 
environmentally benign, biofriendly, single-step/single-phase synthesis method.38 In this 
method dextrose was used as a reducing agent as well as a capping agent for the 
reduction of Au3+ ions in an aqueous buffer at room temperature and atmospheric 
pressure. The synthesized dGNPs were characterized using different analytical 
techniques. To determine the morphology of dGNPs, the absorption spectra were 
observed using Perkin Elmer Lamda 35 UV/vis spectrophotometer. The shape and size of 
the dGNPs were further confirmed by JEOL TEM. EDS (Energy Dispersive 
Spectroscopy) was performed to analyze the elemental composition of nanoparticles 
using JEOL JSM -5400 LV with IXRF system.  
Quantification of dGNPs:  
We determine the concentration of dGNP using reported methods for calculating 
gold atoms per GNP.10,39,40 One mole of any substance contains 6.023 X 1023 atoms 
(Avogadro’s number). For the synthesis of 120 nm GNP, 0.5 mM concentration of Au3+ 
was used. The total number of Au atoms in the solution = 0.500 x 10-3 mol/ liter x 6.023 
x 1023 atoms/ mol= 3.012 x 1020 atoms/ liter.38 We have used the reported equation, for 
 10 
 
calculating number of gold atoms, NAu = (dGNP/nm)3 × 31, where dGNP is the diameter 
of spherical dGNP. 10 Typical dGNP of 120 nm size will have, (120nm/nm) 3 x 31 = 
5.3568 X 107 NAu. Therefore total number of nanoparticles (in 1 mL)/ = NAu (in 1 mL 
sample)/ NAu (in one GNP). Concentration of dGNP with average diameter of 120 nm, in 
one mL sample= 3.115 X 1017 atoms/ 5.3568 X 107 atoms = 5.622 X 109 GNPs/mL. 
Different sizes/ concentrations of dGNPs were obtained by synthesizing them in different 
volumes following the above method. All values for calculation of number of dGNPs are 
within the error range of 102  NPs/ mL. 
Determination of Antibacterial Activity of Sugar Encapsulated GNPs: 
 For each antibacterial experiment the bacteria were cultured fresh by inoculating 
100 µL of bacterial glycerol stock into 10 mL of sterile LB or minimal liquid medium in 
a culture tube. The bacteria were allowed to grow overnight in an incubator maintained at 
37 ºC and shaken at 150 rpm. For all the experiments dGNPs were washed several times 
with sterile water and then resuspended in the nanopure water  
Turbidimetry: 
Turbidimetry is a microbiological assay performed for measuring MIC (minimum 
inhibitory concentration) of dGNPs against E. coli. Various concentrations of dGNPs 
with average diameter of 120 nm (2x1010, 4 x1010, 8 x1010, 16 x1010 NPs/mL), 60 nm 
(2x1011, 4 x1011, 8 x1011, 16 x1011 NPs/mL), 25 nm (16x1012, 32 x1012, 64 x1012, 128 
x1012 NPs/mL) were inoculated with 109 CFU/cm3 in a series of culture tubes containing 
4 mL of sterile liquid media. Control experiments were performed by inoculating the 
media with E. coli in the absence of dGNPs. All the tubes were incubated at 37 ºC and 
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optical density at 600 nm was monitored for 12 h. Increase in OD indicates the 
proliferation/growth of bacteria.41,42  
Spread Plate Technique: 
 The bacteria were grown in a series of culture tubes containing 4 mL of sterile 
liquid media with various concentrations of dGNPs. Cultures from selected 
concentrations and growth points (12 h) were spread onto Luria Bertani or Soy tryptic 
agar plates and incubated at 37 ºC for 12 h to estimate the number of viable bacteria.43  
Agar Plate Diffusion:  
The potency of the antibacterial agent was studied by agar plate diffusion method; 
where in the suspension of the bacteria containing 109 CFU/mL was added to sterile 
nutrient agar medium at 37 ºC and the mixture was allowed to solidify in a petri dish.44-45 
Wells of diameter 0.630 cm were punched in agar plate and filled with 50 µL of either 
various concentrations of nanoparticle suspension (sample) or kanamycin (standard) or 
sterile water (control). Nanoparticles were allowed to diffuse into the agar for one hour at 
4 ºC and the plates were then incubated for 12 h at 37 ºC. After incubation, the radius of 
the zone of bacterial-growth inhibition was measured with an accuracy of ± 0.1 mm. The 
mean inhibition-zone radius was determined. All the experiments were repeated thrice.  
Fluorescence Assay: 
 The bacteria were cultured in liquid media in the presence of dGNPs with 
different concentrations for 12 h at 37 ºC. The samples were collected and centrifuged at 
6000 rpm for 3 min and washed twice with Phosphate Buffer Saline (PBS) (pH ~ 7.2). 
These bacterial cells were incubated with propidium iodide (3 μM in PBS) in the dark for 
30 min at room temperature. Fluorescence detection was performed on 10 μL of the 
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bacterial suspension that was placed on a glass slide and observed under scanning Leica 
fluorescence microscope.10 Positive control was prepared by treating the bacterial 
suspension with 100 % ethyl alcohol for 15 min.  
Preparation for Cross-Section of the Bacterial Cells: 
 Ultrastructural changes induced by dGNP treatment were studied under an 
electron microscope. Cultures of the two bacterial strains were fixed by mixing with 
equal volumes of a 2x fixative solution to give final concentrations of 2.0 % w/v 
paraformaldehyde and 2.5 % w/v glutaraldehyde in 50 mM sodium cacodylate buffer (pH 
7.4). After incubating with fixative for 2 h at room temperature, the fixed samples were 
washed and centrifuged twice; the supernatant was discarded, and the pellet was 
resuspended in 50 mM sodium cacodylate buffer. The same process was followed during 
all subsequent solution changes. Samples were post fixed for 1 h at 25 °C with 1% w/v 
osmium tetroxide in 50 mM sodium cacodylate buffer. The post fixed samples were 
washed with nanopure water twice, and then dehydrated in a graded ethanol series (once 
in 25%, 50%, 75%, and 95% and thrice in 100 % ethanol for 10 min each). The 
dehydrated samples were infiltrated with Spurr’s epoxy resin (once in 33%, 66%, 95% 
and thrice in 100% resin for 1 h each) and then left overnight in 100% resin. The samples 
were centrifuged through fresh resin in BEEM capsules and hardened at 70 °C for 18 h. 
Ultra-thin sections of the pelleted samples were cut on an RMC MT-X ultra microtome 
using glass knives. Sections were stained with 2 % aqueous uranyl acetate and Reynold’s 
lead citrate for 15 min and 3 min respectively, and examined using a JEOL-100CX 
transmission electron microscope.46,47 
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RESULTS AND DISCUSSIONS 
The use of non-bio/ non-ecofriendly synthesis processes, cellular toxicity and 
instability of these nanoparticles limits their application. Taking these into consideration, 
we explored the antibacterial properties of stable, biocompatible eco-friendly dGNPs.  
Synthesis and Characterization of dGNPs: 
 Three different sizes of dGNPs [25 nm, 60 nm and 120 nm (± 5 nm)] were 
synthesized using the previously published method in which dextrose was used as a 
capping and reducing agent (Figure 5).38 dGNPs of different sizes were produced by 
varying the concentrations of KAuCl4. The properties of the synthesized dGNPs were 
characterized using TEM, UV/vis, FTIR and EDS.  
The presence of the dextrose on the surface of dGNPs was determined by the 
Benedict’s test. dGNPs were able to reduce copper sulphate solution which was observed 
by a color change from blue to brick red color (Figure 6).48 Further, the presence of 
unreduced hydroxyl groups on the dGNPs was determined by the volumetric acid-base 
titration. In this experiment, the dGNPs were added to the mixture of pyridine and acetic 
anhydride (2:1).  
 
Figure 4: Reaction scheme showing the acetylation mechanism of alcohols with Ac2O in 
pyridine. 
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This reaction was kept for 30 hrs at 60ºC for complete acetylation of hydroxyl 
groups. The resultant mixture was added to 200 ml ice cold water and titrated against 0.5 
M NaOH with phenolphthalein indicator until the mixture turns pink (Figure 7). Thus the 
results confirmed the presence of reducing hydroxyl groups on the surface of dGNPs.49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 15 
 
 
Figure 5: Representative TEM images of dGNPs of three sizes 25 ± 5 nm (scale bar = 
100 nm); 60 ± 5 nm (scale bar = 200 nm); 120 nm (scale bar = 200 nm) 
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Figure 6: Shows the digital images of (A) unreduced benedicts reagent and (B) reduced 
benedicts reagent in the presence of dGNPs 
                                                                               
                     A                         B 
Figure 7: Shows the digital images of conical flask before (A) and after (B) acid-base 
titration indicating the end point at which the total acid (reaction mixture) in the reaction 
is neutralized using a base (NaOH) 
 
 
 
 
 
 
 
B
dGNPs 
A
 17 
 
Antibacterial Activity: 
 To determine the antibacterial activity of dGNPs, we performed both liquid broth 
and solid agar plate based growth studies on E. coli. The dGNPs of different sizes were 
tested for their antibacterial activity at various concentrations against E. coli. Before 
performing the actual antibacterial experiment the GNPs were tested for their stability by 
suspending the nanoparticles in sterile liquid media in culture tube and kept in an 
incubator shaker at 37⁰C. The dGNPs were found to be intact/ stable (no 
cluster/precipitation) for more than 48 hrs. In the tube assay, the bacterial cells were 
grown in the presence of dGNPs and the growth was monitored hourly by measuring the 
optical density (OD) at 600 nm for 12 h. Blank samples were prepared by suspending the 
dGNPs in sterile liquid medium and processed in the same condition as that of samples. 
Any absorption due to dGNPs was autocorrected using a blank sample. Results were 
plotted with the OD on Y-axis against the time on X-axis (Figure 8). Both the 120 nm 
and 60 nm dGNPs were found to inhibit the proliferation of E. coli, in a concentration 
dependent manner with minimum inhibitory concentrations (MIC) at 16×1010 NPs/mL 
and 16×1011 NPs/mL respectively. The 25 nm dGNPs did not significantly affect the 
proliferation of E. coli even at a concentration as high as 128×1012 NP/mL. The 120 nm 
dGNPs were found to be the most potent antibacterial agent compared with the 60 nm 
which in turn were more potent than the 25 nm (Figure 8). The growth kinetic data 
clearly suggested that the antibacterial activity was directly proportional to the increase in 
size of dGNPs.  
The antibacterial activity exhibited by dGNPs could be attributed to the presence 
of free Au3+ ions that remained in solution when the dGNPs were suspended in water or 
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due to changes in pH, since the bacterial activity is sensitive to both of these factors. To 
quantify the free Au3+ ions in the suspension, the dGNPs precipitated by centrifugation 
and the supernatant was tested for the presence of free Au3+ ions by measuring the 
absorbance at 290 nm. The near zero absorbance at 290 nm, showed the absence of any 
free Au3+ ion (data not shown) suggesting that the free Au3+ ion concentration in the 
dGNPs suspension was insignificant and, therefore, not responsible for antibacterial 
activity. In addition, the pH of the dGNPs suspensions was at 7.2-7.4 which is the normal 
pH range for the microorganisms environment. Hence, pH could not have been 
responsible for the antibacterial activity. Taken together, the results suggested that the 
antibacterial activity was due to the dGNPs and not due to free Au3+ ion or change in pH.  
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Figure 8: Effect of different sizes of dextrose encapsulated GNPs on the growth of E. 
coli. Growth analysis curves were measured by monitoring the optical density (OD) at 
600 nm and the E.coli was treated with dGNPs of sizes: 25±5 nm; 60±5 nm and 120±5 
nm at different concentrations (NPs/ ml). 
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Results of the growth assay indicated that the presence of dGNPs inhibited the 
growth of E. coli, representing the bacteriostatic property of the dGNPs. In order to 
confirm whether dGNPs exhibited bactericidal action, spread plate technique was used. 
The cultures in the liquid broth that were treated with different sizes of dGNPs for 12 h 
[the time required by control to reach the stationary phase (complete growth)] were 
plated on fresh LB agar media. The results given in (Figure 9-I-A & B) indicated that the 
number of colonies on the agar plate significantly decreased with increase in the size of 
dGNPs. The antibacterial potency of dGNPs increased as the size increased (25 nm < 60 
nm < 120 nm). Furthermore, the growth of the colonies on the agar plate demonstrated 
that within one size of dGNPs, the bactericidal effect was concentration dependent 
(Figure 9-I-A & B). The above results from the agar spread plate methods confirmed that 
the dGNPs exhibited bactericidal properties. Also, when compared with the potency of 
standard antibiotic Kanamycin (Figure 9-II-A & B), the dGNPs with sizes 120 nm and 60 
nm, at their respective highest concentration (16×1010 NPs/mL and 16×1011 NPs/mL 
respectively), retarded the bacterial growth to the same extent as 5.0 mg/mL 
concentration of kanamycin (Figure 9-III-A).  
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Figure 9: I.(A)  Plate assay showing the number of viable cells recovered after the 
treatment of E. coli without (control) or with presence of dGNPs of sizes; 25±5 nm, 60±5 
nm, and 120±5 nm at different concentrations (NPs/ ml). I.(B) Graphs plotted for number 
of E.coli colonies recovered, against concentration of dGNPs. II.(A) Plate assay showing 
the number of viable cells recovered after the treatment of E. coli without (control) or 
with different concentrations of kanamycin. II.(B) Graphs plotted for number of E.coli 
colonies recovered against different kanamycin concentrations.  III. Comparison plot for 
the number of E.coli colonies recovered against different antimicrobial agents (dGNPs & 
kanamycin). 
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Agar plate diffusion is a microbiological assay used for comparing the potency of 
unknown antimicrobial with a known standard antibiotic against the bacteria grown in 
solid media. In this context, to determine the antibacterial potency of the GNPs, we 
performed agar plate diffusion (APD) assay. We performed the APD assay using dGNPs 
(Figure 10-I-A & B) and a standard antibiotic kanamycin, (Figure 10-II-A & B) against 
E. coli. The results indicated that the 120 nm and 60 nm GNPs attenuated the bacterial 
growth with increasing number of nanoparticles [NPs/mL (Table. 1)]. However, the 25 
nm GNPs did not show any zone of inhibition, indicating that this size was an inefficient 
antibacterial agent. At 1/ 10th the number of NPs of 120 nm showed the same extent of 
radius of inhibition zone as that shown by number of NPs of 60 nm, which proves 120 
nm to be more efficient antibacterial agent. 
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Figure 10: I. Potency of the GNPs as anti-bacterial agents against E. coli shown as (A) 
Images of petri dishes showing the retardation of bacterial growth at different 
concentrations of GNPs of sizes 25±5 nm, 60±5 nm, and 120±5 nm. (B) Graphs plotted 
with averaged radius of inhibition zone against the concentrations of the GNPs. II. (A) 
Potency of the kanamycin against E. coli. Image of petri dishes showing the retardation of 
bacterial growth at different concentrations of kanamycin. (B) Graphs plotted with averaged 
radius of inhibition zone against the concentrations of kanamycin. 
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Type of Bacteria 
 
120 nm 
 
 
60 nm 
 
 
25 nm 
 
E. coli 
 
 
16 x 1010 NPs/ ml 
(± 102 NPs/ ml) 
 
 
16 x 1011 NPs/ ml 
(± 102 NPs/ ml) 
 
128 x 1012 NPs/ ml 
(± 102 NPs/ ml) 
 
S. epidermidis 
 
 
16 x 1010 NPs/ ml 
(± 102 NPs/ ml) 
 
 
16 x 1011 NPs/ ml 
(± 102 NPs/ ml) 
 
128 x 1012 NPs/ ml 
(± 102 NPs/ ml) 
 
Table 1: Representing concentrations of dGNPs of three different sizes used to treat 
bacteria. 
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dGNPs Induced Disruption of Bacterial Cells: 
 To determine the mechanism of the antibacterial activity of dGNPs, time 
dependent action of dGNPs on the morphology of bacterial cell was monitored. This was 
done by collecting E. coli cells treated with dGNPs at different time points and were 
processed for cross sectional analysis. TEM analysis of the cross sections of untreated 
cells showed that the membrane integrity remained intact at different time points even 
after the stationary phase (after 12 hours) (Figure 11-I-a & b). However, bacteria treated 
with 120 nm and 60 nm dGNPs showed gradual morphological changes within six hours. 
Initially, the dGNPs were observed to anchor onto the surface of the cell at several sites 
(Figure 11-II-a). Gradually, the sites where dGNPs lodged, showed the formation of 
perforations or Outer Membrane Vesicles (OMVs) on the membrane, which eventually 
resulted into complete cell lysis (Figure 11-II-b & c).50,51  
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Figure 11: Visualization of dGNP induced morphological changes in E. coli cell 
membranes under the TEM. I-a. Morphology of the untreated E. coli cell at 0 h; I-b. 
Cross-section of the untreated E. coli cell after 12 h; II-a. Interaction of dGNPs with 
E.coli cell at 0 h; II-b. Cross-section of the dGNPs treated E.coli cell after 6 h showing 
the initiation of the cell disruption by the formation of outer membrane vesicles (OMVs); 
II-c. Cross-section of the lysed E.coli cell after 12 h of treatment with dGNPs; II-d. The 
magnified view of OMV formation, which represents the initiation of disruption of cell 
membrane. 
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To investigate the effect of various sizes of dGNPs on the cell permeability, cells 
were treated with propidium iodide (PI). PI is a fluorescent dye, which specifically binds 
with nucleic acid and produce enhanced fluorescence. However, PI cannot cross intact 
membranes and is excluded from viable cells.10 Thus, in the presence of PI, cells with 
permeable membrane (lysed or damaged cell membrane) will fluoresce under the 
fluorescence microscope. For this study, we incubated fresh E. coli cultures with different 
sizes of dGNPs and then treated with PI to assess the integrity of the cell membrane. 
Fluorescence images showed that the permeability of dGNP treated bacteria was 92% for 
120 nm, 87% for 60 nm and very minimal permeability of less than 13 % for 25 nm 
(Figure 12-A). The permeability of the cell membrane increased significantly with 
exposure to increase in the size of dGNPs and also with the increase in the concentration 
of dGNPs as evidenced clearly in Figure 12-B. Therefore, exposure of the cells to dGNPs 
leads to the disruption of the integrity of the cell membrane causing increased 
permeability and possible leaching of the cell materials. These results indicated the size 
dependent effect of the dGNPs on bacterial membrane through the time dependent 
leaching /disruption. It must be noted that the mechanism of interaction between the cell 
membrane and the dGNPs needs to be investigated.  
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Figure 12: Monitoring dGNPs induced permeability of E. coli cell membranes and 
leakage of nucleic acids via propidium iodide. (A) The left half shows an image in the 
differential interference contrast mode while the right half shows the corresponding 
fluorescence image. (B) The percentage of cells with permeable membranes from 5 or 
more fields of view obtained by two independent experiments. 
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To determine the antibacterial nature of dGNPs, we further performed 
antibacterial experiments against Staphylococcus epidermidis. Staphylococcus is a genus 
of Gram positive bacteria, which resides normally on the skin and mucous membranes of 
human and other organisms causing a wide array of disease.52-54 Plate based growth 
studies showed similar results to those against E. coli, indicating less number of 
recovered cells with increasing size of dGNPs as well as with increase in the 
concentration of particles Also potency of dGNPs (Figure 13- I-A & B) with sizes 120 
nm and 60 nm at their respective highest concentration (16×1010 NPs/mL and 16×1011 
NPs/mL respectively), was found to be similar to that of standard antibiotic kanamycin 
(Figure 13-II-A & B), at concentration of 2.5 mg/mL (Figure 13-III). 
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Figure 13: I.(A)  Plate assay showing the number of viable cells recovered after the 
treatment of S. epidermidis without (control) or with presence of GNPs of sizes; 25±5 
nm, 60±5 nm, and 120±5 nm at different concentrations (NPs/ ml). I.(B) Graphs plotted 
for number of S. epidermidis colonies recovered, against concentration of dGNPs. II.(A) 
Plate assay showing the number of viable cells recovered after the treatment of S. 
epidermidis without (control) or with presence of different concentrations of kanamycin. 
II.(B) Graphs plotted for number of S. epidermidis colonies recovered against different 
kanamycin concentrations.  III. Comparison plot of the number of S. epidermidis colonies 
recovered on against different microbial agents (dGNPs & kanamycin). 
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Results of the TEM and fluorescence microscopy analysis suggested that the 
antibacterial activity of dGNPs against S. epidermidis also occurred through the 
disruption of bacterial cellular membrane, which was similar to that of E. coli (Figure 14 
& 15).  
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Figure 14: Monitoring dGNPs induced permeability of S. epidermidis cell membranes 
and leakage of nucleic acids via propidium iodide. (A) The left half shows an image in 
the differential interference contrast mode while the right half shows the corresponding 
fluorescence image. (B) The percentage of cells with permeable membranes from 5 or 
more fields of view obtained by two independent experiments.  
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Figure 15: Visualization of dGNP induced morphological changes in S. epidermidis cell 
membranes under the TEM. I-a. Morphology of the untreated S. epidermidis cell at 0 h; I-
b. Cross-section of the untreated S. epidermidis cell after 12 h; II-a. Interaction of dGNPs 
with S. epidermidis cell at 0 h; II-b. Cross-section of the dGNPs treated S. epidermidis 
cell after 6 h showing the initiation of the cell disruption; II-c. Cross-section of the lysed 
S. epidermidis cell after 12 h of treatment with dGNPs. 
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Overall the result suggested similar potency and membrane disruption 
process/mechanism for the antibacterial activity of dGNPs towards Gram negative as 
well as Gram positive bacteria. Dextrose is a polyhydroxylated molecule, which can act 
both as a hydrogen bond donor as well as a hydrogen bond acceptor. Though modified, 
the capping ligand dextrose still possessed the properties of reducing sugar (unmodified 
dextrose). Benedicts test was performed to confirm the presence of reducing sugar. Also 
the presence of unmodified (unreduced) hydroxyl group was confirmed using volumetric 
titration. The presence of reducible hydroxyl group can thus be attributed to the strong 
electrostatic interaction between dGNPs and both gram negative and gram positive 
bacteria, which in turn lead to the disruption of cell membrane. Thus, this may explain 
the versatile antibacterial activity of these dGNPs. It may be inferred that the ligand 
molecule dextrose plays a crucial role in the antibacterial action but the mechanism of 
interaction remains to be established.  
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CONCLUSION 
Antibacterial activity of bio-friendly/ eco-friendly dextrose encapsulated GNPs of 
sizes 25 nm, 60 nm and 120 nm (±5), were investigated. These GNPs showed significant 
antibacterial activity against both Gram-negative as well as Gram-positive bacteria 
without the need for external sources of energy. The efficiency of antibacterial activity 
was directly proportional to the increase in size as well as the concentration of dGNPs. 
These dGNPs were found to exert their antibacterial action via disruption of the cell 
membrane leading to possible leakage of the cytoplasmic contents including nucleic 
acids. These results suggest, it is plausible that the amphoteric nature of dextrose (the 
capping ligand) might be responsible for the interaction of dGNPs with both the Gram-
positive and Gram-negative bacteria which, in turn, leads to the antibacterial activity. The 
antibacterial property of the dGNPs holds promise for pharmaceutical and disinfectant 
applications and other biomedical applications. The molecular level interaction between 
the cell membrane and the dGNPs that causes membrane rupture remains to be 
established. 
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FUTURE STUDIES 
The advancement of nanotechnology, which is considered as a most promising 
technology in the future, needs environmental friendly synthesized nanoparticles. The 
method used in this paper is completely Green Method; hence, this method can find a 
variety of applications in various fields. Moreover, because of the biocompatibility, it has 
wide applications in the field of biomedicine. Nanoparticles can also be used in the 
treatment of various diseases and also in drug delivery. Though our nanoparticles were 
proved to be antimicrobial, further effort to be made to determine its cytotoxicity and also 
to explore the other activities of these dGNPs. 
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